Non-invasive retinal Leverage Amydis’s non-invasive ocular tracer technology and eye-based diagnostics to position as a non-surgical screening option for neurodegenerative diseases, expanding to ALS, FTD, LATE and Alzheimer's cohorts where there is high demand for early detection.

AI enabled Capitalize on their plan to build a multi-omics ocular data warehouse and AI-enabled health insights to offer data-driven biomarker analysis services, enabling partnerships with healthcare providers and pharma for targeted trial recruitment and companion diagnostics.

NIH funding Target NIH and government-funded programs as potential co-development or grant-funded collaboration opportunities, given recent Phase II SBIR awards and NIH grants for TDP-43 detection and retinal biomarkers, indicating strong validation and funding readiness.

Clinical adoption Position products as compatible with routine ophthalmic imaging workflows to ease adoption by clinics, offering turnkey tracing agents and image analysis tools that fit existing equipment from common tech stacks and imaging centers.

Strategic partnerships Explore partnerships with biopharma and diagnostics players focused on neurodegenerative, cardiovascular, and ocular diseases to co-develop tracers, validation studies, and market-ready tests that leverage Amydis’s eye as a window to the body.